Eligibility: Inclusion Criteria: Cohort 1: Deucravacitinib-exposed cohort * Currently pregnant during the enrollment period * Diagnosed with psoriasis (PsO) validated by medical records when possible * Exposure to deucravacitinib for any number of days, at any dose, and at any time from 2 d…

Eligibility: Inclusion Criteria: * Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening. * Have moderate to severe plaque psoriasis at Baseline as defined by 1. BSA ≥5% OR 2. sPGA ≥3 (moderate to severe) OR 3. PASI ≥5 * Must have been prescribed, per standar…

Eligibility: Inclusion Criteria: * Japanese adult participants aged 18 years old or older * Physician-reported diagnosis of plaque psoriasis * Newly initiating deucravacitinib or apremilast according to the label * Participants who have signed informed consent Exclusion Criteria: * Partici…

Eligibility: Key inclusion criteria: 1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, as per provincial reimbursement criteria 2. Adult patients at the time of informed consent signature 3. Patients able to understand and willing to comply with protocol requirements,…

Eligibility: Inclusion Criteria: * Active plaque psoriasis (PASI ≥3) or Psoriatic Arthritis fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) and not meeting MDA criteria * on stable baseline psoriatic treatment for 12 weeks before enrollment * ≥ 18 years old Exclusion…

Eligibility: Inclusion Criteria: * Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment. * Treatment with risankizumab is indicated per summary of…

Eligibility: Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by * BSA 10% * PGA ≥3 * PASI ≥12 3. Must be a candidate for phototherapy and/or systemic therapy 4. Females of childbearing potent…

Eligibility: Inclusion Criteria: * Aged 18-65 years. * Diagnosed with RA, PsA or axSpA by a rheumatologist. * Undertakes paid work (full- or part-time work or studying). * Able to read and understand Danish. * Answers 'unlikely' or 'not certain' to question #6 from the WAI questionnaire: 'Do…

Eligibility: * INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Meets one of the following: 1. Has documentation of PID confirmed by genetic evaluation demonstrating a deleterious variant in the gene (or…

Eligibility: Inclusion Criteria: * Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology) * Social insured * Have the capacity to understand the study requi…

Eligibility: Inclusion Criteria: \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) wi…

Eligibility: Inclusion Criteria: * Have been diagnosed with plaque psoriasis by a dermatologist * Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) * Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of…

Eligibility: Inclusion criteria: 1. A diagnosis of one of the following: Rheumatoid Arthritis (RA), Sjogren's Syndrome, Systemic lupus erythematosus (SLE), Mixed connective tissue disease (MCTD), or Psoriatic Arthritis (PsA), as documented by their treating specialist or primary care provide…

Eligibility: Inclusion Criteria: * Patients 18 years or older with a diagnosis of psoriasis will be invited to participate Exclusion Criteria: * Patients not able to cooperate to the study * Patients unable understand and sign informed consent

Eligibility: Inclusion Criteria: * At least 18 years of age inclusive, at the time of signing the informed consent form (ICF) * Have a palmoplantar pustulosis (PPP) diagnosis for at least 24 weeks prior to the Screening Visit * Have PPPASI ≥12 at the Screening Visit and Baseline Visit * Have…

Eligibility: Inclusion Criteria: * Patients can have either histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, or have a malignancy for which a PD-1/PD-L1 inhibitor has been approved in the adjuvant setting. Eligible tumor types include solid…

Eligibility: Inclusion Criteria: 1. Adults with diagnosis of PsA fulfilling the classification for PsA (CASPAR) criteria. 2. Must have: 1 or more swollen joint(s) and/or one or more active sites of enthesitis 3\. AND/OR 1 or more psoriatic plaques 4\. No changes in the regular medication…

Eligibility: Inclusion criteria: * Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment * Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab *…

Eligibility: Inclusion Criteria: * Adults (\>18 year) * Both sexes * Must have a history of psoriasis of at least 3% body surface area affected by skin psoriasis (in a body area that the subject will allow the PI to perform several skin biopsies as noted below (optional)) and may carry a dia…

Eligibility: Inclusion Criteria: 1. The subject understands the information provided, gives informed consent to participate in the study and is deemed by the investigator to be able to participate, 2. a skin condition that is expected to respond well to targeted UVB treatment, 3. a signed co…